Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases
Cancer Letters, 05/11/2012Goyal J et al.
Radium–223 is the first agent in this class to show an overall survival advantage in CRPC patients with bone metastases. This landmark finding will likely have a considerable impact on the treatment paradigm of bone–metastatic castration–resistant prostate cancer (CRPC), and will pave the way for further developments in the future.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.